Alexion Pharmaceuticals Inc. has been left disappointed by top-line data from the Phase II/III registration trial for its first-in-class terminal complement inhibitor Soliris (eculizumab) in preventing delayed graft function (DGF) after kidney transplantation in adult recipients of a deceased donor kidney.
If successful, the study could have paved the way for approval in another indication for Alexion’s mainstay and multibillion-dollar selling...